Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1991 3
1998 3
1999 1
2000 2
2005 2
2006 3
2007 2
2008 1
2009 1
2010 4
2011 2
2012 3
2013 4
2014 2
2015 4
2016 5
2017 2
2018 3
2019 7
2020 6
2021 4
2022 5
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Low Grade Lung Neuroendocrine Neoplasm"
Page 1
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Caplin ME, et al. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. Ann Oncol. 2015. PMID: 25646366 Free article. Review.
PATIENTS AND METHODS: Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'bronchial neuroendocrine tumors', 'bronchial carcinoid tumors', 'pulmonary carcinoid', 'pulmonary typical/atypical carcin …
PATIENTS AND METHODS: Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'br …
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F, Berruti A. Amoroso V, et al. ESMO Open. 2023 Apr;8(2):100787. doi: 10.1016/j.esmoop.2023.100787. Epub 2023 Feb 24. ESMO Open. 2023. PMID: 36842300 Free PMC article. Review.
It is unknown if the irAE occurrence is a valid surrogate of ICIs' efficacy. METHODS: We identified articles reporting the results of randomized trials of experimental ICI therapy in solid tumors with a systematic search. ...In the non-small-cell lung cancer …
It is unknown if the irAE occurrence is a valid surrogate of ICIs' efficacy. METHODS: We identified articles reporting the results of ran …
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. Patel SP, et al. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969335 Free PMC article. Clinical Trial.
PURPOSE: Immune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ant …
PURPOSE: Immune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare …
Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes.
Brighi N, Lamberti G, Manuzzi L, Maggio I, Campana D. Brighi N, et al. Anticancer Drugs. 2019 Aug;30(7):e0784. doi: 10.1097/CAD.0000000000000784. Anticancer Drugs. 2019. PMID: 30896503 Review.
Typical (TC) and atypical (AC) carcinoids are low-grade neuroendocrine tumors (NETs) of the lung and, are neglected diseases in respect of both high-grade NETs of the lung (i.e. small-cell lung cancer and large-cell neuro …
Typical (TC) and atypical (AC) carcinoids are low-grade neuroendocrine tumors (NETs) of the lung and, are …
Neuroendocrine breast carcinoma: a rare but challenging entity.
Trevisi E, La Salvia A, Daniele L, Brizzi MP, De Rosa G, Scagliotti GV, Di Maio M. Trevisi E, et al. Med Oncol. 2020 Jul 25;37(8):70. doi: 10.1007/s12032-020-01396-4. Med Oncol. 2020. PMID: 32712767 Free PMC article. Review.
Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast carcinoma (NEBC), includes a heterogeneous group of rare tumors, which account for 2-5% of all invasive breast carcinomas. Because of their low incidence, most of …
Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast carcinoma (NEBC), includes a heterog …
Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G, Wang Y, Zhang H, She X, Yang J. Xu G, et al. Future Oncol. 2021 Mar;17(9):1069-1081. doi: 10.2217/fon-2020-0703. Epub 2020 Nov 2. Future Oncol. 2021. PMID: 33136448 Review.
Neuroendocrine neoplasias (NENs) are a heterogeneous group of rare tumors scattered throughout the body. Surgery, locoregional or ablative therapies as well as maintenance treatments are applied in well-differentiated, low-grade NENs, whereas cytotoxic …
Neuroendocrine neoplasias (NENs) are a heterogeneous group of rare tumors scattered throughout the body. Surgery, locoregional …
Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms.
Baudin E, Hayes AR, Scoazec JY, Filosso PL, Lim E, Kaltsas G, Frilling A, Chen J, Kos-Kudła B, Gorbunova V, Wiedenmann B, Nieveen van Dijkum E, Ćwikła JB, Falkerby J, Valle JW, Kulke MH, Caplin ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Baudin E, et al. Neuroendocrinology. 2019;108(1):7-17. doi: 10.1159/000493980. Epub 2018 Sep 24. Neuroendocrinology. 2019. PMID: 30248673 Free article. Review.
Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of …
Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified a …
Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.
Hendifar AE, Marchevsky AM, Tuli R. Hendifar AE, et al. J Thorac Oncol. 2017 Mar;12(3):425-436. doi: 10.1016/j.jtho.2016.11.2222. Epub 2016 Nov 24. J Thorac Oncol. 2017. PMID: 27890494 Free article. Review.
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and gastrointestinal tract. Lung NETs can be classified as well differentiate …
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throug …
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Thomas KEH, Voros BA, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA. Thomas KEH, et al. Oncologist. 2019 Aug;24(8):1076-1088. doi: 10.1634/theoncologist.2018-0604. Epub 2019 Jan 11. Oncologist. 2019. PMID: 30635447 Free PMC article. Review.
Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) are a rare neoplasm with a bleak prognosis. ...Food and Drug Administration approval of peptide receptor radionuclide therapy in low- and intermediate-grade neuroendocr …
Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) are a rare neoplasm with a bleak prognosis. . …
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
Minczeles NS, Hofland J, de Herder WW, Brabander T. Minczeles NS, et al. Curr Oncol Rep. 2021 Mar 15;23(4):46. doi: 10.1007/s11912-021-01037-7. Curr Oncol Rep. 2021. PMID: 33721105 Free PMC article. Review.
PURPOSE OF REVIEW: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms …
PURPOSE OF REVIEW: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)] octreotate is an effective and safe second- or …
67 results